These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Failure of recognition of drug-induced parkinsonism in the elderly. Esper CD; Factor SA Mov Disord; 2008 Feb; 23(3):401-4. PubMed ID: 18067180 [TBL] [Abstract][Full Text] [Related]
6. Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson's disease. Jeong S; Cho H; Kim YJ; Ma HI; Jang S PLoS One; 2021; 16(3):e0247354. PubMed ID: 33647030 [TBL] [Abstract][Full Text] [Related]
7. The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. Munhoz RP; Werneck LC; Teive HA Clin Neurol Neurosurg; 2010 Jun; 112(5):431-5. PubMed ID: 20347518 [TBL] [Abstract][Full Text] [Related]
8. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. Mahmoud F; Tampi RR Am J Geriatr Pharmacother; 2011 Dec; 9(6):405-12. PubMed ID: 21993183 [TBL] [Abstract][Full Text] [Related]
9. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Bondon-Guitton E; Perez-Lloret S; Bagheri H; Brefel C; Rascol O; Montastruc JL Mov Disord; 2011 Oct; 26(12):2226-31. PubMed ID: 21674626 [TBL] [Abstract][Full Text] [Related]
10. Cognitive dysfunction in drug induced parkinsonism (DIP). Kim YD; Kim JS; Chung SW; Song IU; Yang DW; Hong YJ; Kim YI; Ahn KJ; Kim HT; Lee KS Arch Gerontol Geriatr; 2011; 53(2):e222-6. PubMed ID: 21163539 [TBL] [Abstract][Full Text] [Related]
12. Drug-induced parkinsonism. Mena MA; de Yébenes JG Expert Opin Drug Saf; 2006 Nov; 5(6):759-71. PubMed ID: 17044803 [TBL] [Abstract][Full Text] [Related]
13. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. Knol W; Keijsers CJ; Jansen PA; van Marum RJ J Clin Psychopharmacol; 2010 Feb; 30(1):57-63. PubMed ID: 20075649 [TBL] [Abstract][Full Text] [Related]
14. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Kane JM; Leucht S; Carpenter D; Docherty JP; J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142 [TBL] [Abstract][Full Text] [Related]
15. Diabetes mellitus and drug-induced Parkinsonism: a case-control study. Ma HI; Kim JH; Chu MK; Oh MS; Yu KH; Kim J; Hahm W; Kim YJ; Lee BC J Neurol Sci; 2009 Sep; 284(1-2):140-3. PubMed ID: 19467671 [TBL] [Abstract][Full Text] [Related]
16. Drugs inducing or aggravating parkinsonism: a review. Marti-Massó JF; Poza JJ; Lopez de Munain A Therapie; 1996; 51(5):568-77. PubMed ID: 9138399 [TBL] [Abstract][Full Text] [Related]
17. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
18. Drugs with anticholinergic properties: a current perspective on use and safety. Gerretsen P; Pollock BG Expert Opin Drug Saf; 2011 Sep; 10(5):751-65. PubMed ID: 21635190 [TBL] [Abstract][Full Text] [Related]
19. [Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance]. Llau ME; Nguyen L; Senard JM; Rascol O; Montastruc JL Rev Neurol (Paris); 1994 Nov; 150(11):757-62. PubMed ID: 7597368 [TBL] [Abstract][Full Text] [Related]